Successful mobilization of peripheral blood stem cells with bortezomib + high-dose cyclophosphamide + G-CSF in a light chain myeloma patient after failure with Total Therapy 2.
Autologous stem cell transplantation is considered the best post-induction therapy for multiple myeloma (MM). Therefore, therapy for myeloma should be chosen not only on the basis of efficacy, but also taking into account their impact on the hematopoietic stem cell compartment. We describe the case of a MM patient in which a successful mobilization of peripheral stem cells was obtained with bortezomib, cyclophosphamide and G-CSF, after two failed attempts in the framework of Total Therapy 2. The patient underwent an autologous transplantation, showing a rapid and complete post-transplant hematological recovery. Our experience suggests that bortezomib is an effective anti-myeloma agent without negative impact on stem cell mobilization, even in patients with a previous history of failed harvest.
Giglio
Gianfranco
G
Oncology Regional Department, Oncology and Hematology Units, "A.Cardarelli" Hospital, C.da Tappino, 86100, Campobasso, Italy. gianfrancogiglio@alice.it.
Romito
Sante
S
Oncology Regional Department, Oncology and Hematology Units, "A.Cardarelli" Hospital, C.da Tappino, 86100, Campobasso, Italy.
Carrozza
Francesco
F
Oncology Regional Department, Oncology and Hematology Units, "A.Cardarelli" Hospital, C.da Tappino, 86100, Campobasso, Italy.
Musacchio
Michela
M
Oncology Regional Department, Oncology and Hematology Units, "A.Cardarelli" Hospital, C.da Tappino, 86100, Campobasso, Italy.
Antuzzi
Giustino
G
Oncology Regional Department, Oncology and Hematology Units, "A.Cardarelli" Hospital, C.da Tappino, 86100, Campobasso, Italy.
Gigli
Rosanna
R
Laboratory Medicine Unit, "A.Cardarelli" Hospital, Campobasso, Italy.
Magri
Marilù
M
Laboratory Medicine Unit, "A.Cardarelli" Hospital, Campobasso, Italy.
Bavaro
Pasqua
P
Department of Hematology, Hematological Intensive Care for Hematopoietic Transplantation Unit, Pescara Hospital, Pescara, Italy.
Di Bartolomeo
Paolo
P
Department of Hematology, Hematological Intensive Care for Hematopoietic Transplantation Unit, Pescara Hospital, Pescara, Italy.
Dell'Isola
Mario
M
Department of Transfusional Medicine, Apheresis Unit, Pescara Hospital, Pescara, Italy.
Accorsi
Patrizia
P
Department of Transfusional Medicine, Apheresis Unit, Pescara Hospital, Pescara, Italy.
D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D003520:Cyclophosphamide / Q000008:administration & dosage*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D007147:Immunoglobulin Light Chains; D008297:Male; D009101:Multiple Myeloma / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D011719:Pyrazines / Q000008:administration & dosage*; D014182:Transplantation, Autologous
D018906:Antineoplastic Agents, Alkylating; D001897:Boronic Acids; D007147:Immunoglobulin Light Chains; D011719:Pyrazines; D016179:Granulocyte Colony-Stimulating Factor; D000069286:Bortezomib; D003520:Cyclophosphamide